Cargando…

Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations

BACKGROUND: A lack of biomarkers that identify patients at risk for severe osteoarthritis (OA) complicates development of disease-modifying OA drugs. OBJECTIVE: To determine whether inflammatory genetic markers could stratify patients with knee OA into high and low risk for destructive disease. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Attur, Mukundan, Wang, Hwa-Ying, Kraus, Virginia Byers, Bukowski, Jack F, Aziz, Nazneen, Krasnokutsky, Svetlana, Samuels, Jonathan, Greenberg, Jeffrey, McDaniel, Gary, Abramson, Steven B, Kornman, Kenneth S
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925146/
https://www.ncbi.nlm.nih.gov/pubmed/19934104
http://dx.doi.org/10.1136/ard.2009.113043
Descripción
Sumario:BACKGROUND: A lack of biomarkers that identify patients at risk for severe osteoarthritis (OA) complicates development of disease-modifying OA drugs. OBJECTIVE: To determine whether inflammatory genetic markers could stratify patients with knee OA into high and low risk for destructive disease. METHODS: Genotype associations with knee OA severity were assessed in two Caucasian populations. Fifteen single nucleotide polymorphisms (SNPs) in six inflammatory genes were evaluated for association with radiographic severity and with synovial fluid mediators in a subset of the patients. RESULTS: Interleukin 1 receptor antagonist (IL1RN) SNPs (rs419598, rs315952 and rs9005) predicted Kellgren–Lawrence scores independently in each population. One IL1RN haplotype was associated with lower odds of radiographic severity (OR=0.15; 95% CI 0.065 to 0.349; p<0.0001), greater joint space width and lower synovial fluid cytokine levels. Carriage of the IL1RN haplotype influenced the age relationship with severity. CONCLUSION: IL1RN polymorphisms reproducibly contribute to disease severity in knee OA and may be useful biomarkers for patient selection in disease-modifying OA drug trials.